POLE3
DNA polymerase epsilon subunit 3
As of the edition of 20 October 2026, POLE3 (DNA polymerase epsilon subunit 3, UniProt Q9NRF9) has 2 drugs tested at it and 2 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NRF9
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Lungs and airways
- Registered trials of its drugs
- 8
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| TAR-200 | Active | Phase 3 | none listed |
| FF-10832 | Active | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 2 |
| Total on the list | 2 |